This ancient Indian seashell trick can help with sleep apnea — and reduce snoring
Nearly 54 million US adults are believed to suffer from obstructive sleep apnea (OSA), which occurs when muscles in your throat relax and repeatedly block your airway, causing you to stop breathing as you sleep.
Besides disrupted sleep and snoring, OSA can raise the risk of high blood pressure, heart disease, Type 2 diabetes, stroke and car crashes.
'The standard treatment for OSA is a continuous positive airway pressure machine, or CPAP, which keeps the patient's airway open by blowing air through a facemask throughout the night,' said Dr. Krishna K. Sharma from the Eternal Heart Care Centre and Research Institute in Jaipur, India.
'While effective, many patients find it uncomfortable and struggle to use it consistently.'
Sharma is conch-fident that an ancient Indian practice known as shankh blowing can ease OSA symptoms without the hassle of a costly machine.
He led a small study that reported that OSA patients who regularly blew into a conch for six months had fewer breathing interruptions at night and more alertness during the day.
'In my clinical practice, several patients reported feeling more rested and experiencing fewer symptoms after regularly practicing shankh blowing — a traditional yogic breathing exercise involving exhaling through a conch shell,' Sharma said.
'These observations led us to design a scientific study to rigorously test whether this simple, ancient practice could serve as a meaningful therapy for people with OSA.'
Thirty people between 19 and 65 years old were divided into two groups — 16 blew through a conch shell while 14 engaged in a deep breathing exercise.
The conch group underwent training and daily practice sessions at home before the study commenced.
Eternal Heart tracked the participants, who had moderate OSA, from May 2022 to January 2024.
They were monitored while sleeping and asked about their sleep quality and daytime sleepiness.
After six months, the conch group was 34% less sleepy during the daytime than the deep breathing group.
Medical testing showed that the conch group participants had an average of four or five fewer episodes where their breathing stopped during sleep. They also had higher levels of oxygen in their blood at night.
The conch-lusions were published this week in the ERJ Open Research journal.
'For people living with OSA, especially those who find CPAP uncomfortable, unaffordable or inaccessible, our findings offer a promising alternative,' Sharma said.
'Shankh blowing is a simple, low-cost breathing technique that could help improve sleep and reduce symptoms without the need for machines or medication.'
Blowing shankhs can cost anywhere from $20 to over $100.
The theory is that shankh blowing strengthens muscles crucial to maintaining an open airway during sleep.
Dr. Sophia Schiza — a professor of respiratory and sleep medicine at the University of Crete in Greece and head of the European Respiratory Society group on sleep-disordered breathing — called it an 'intriguing study.'
'A larger study will help provide more evidence for this intervention, which could be of benefit as a treatment option or in combination with other treatments in selected OSA patients,' said Schiza, who was not involved in this research.
Sharma is planning a larger trial involving several hospitals, a longer study period and more severe forms of OSA.
The team wants to further explore how shankh blowing affects airway muscle tone, oxygen levels and sleep and compare it against treatments like CPAP.
Losing weight, exercising and abstaining from alcohol can also help OSA, along with oral devices, a different sleep position and surgery in severe cases.
Solve the daily Crossword
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
AleraCare and PURE Healthcare Announce Intent to Merge
The combined company will create a leading ambulatory infusion platform with more than 75 outpatient locations across 14 states throughout the U.S. PHOENIX & TAYLORSVILLE, Utah, August 13, 2025--(BUSINESS WIRE)--AleraCare, a leading provider of infusion and specialty pharmacy services across the U.S., and PURE Healthcare, a leading national medical group that delivers healthcare services for individuals with complex chronic conditions such as rheumatoid arthritis, Crohn's disease, multiple sclerosis, Alzheimer's disease and other autoimmune conditions, today announced that the businesses have entered into a definitive merger agreement. Terms of the transaction were not disclosed. The proposed merger creates an unprecedented opportunity to provide high-quality patient care, improve clinical outcomes and enhance the availability of infusion services that lower the overall cost to the healthcare system overall. Founded in 2019, AleraCare's core lines of business include ambulatory infusion centers, home infusion therapy and specialty pharmacy. Administered at convenient, accessible, patient-first locations, AleraCare is focused on maintaining trusted-partner status with physicians, payors, drug distributors and pharmaceutical manufacturers. The company has rapidly expanded to over 30 ambulatory infusion centers across the country and is a provider-of-choice for infusion services to high-need and medically complex populations. Pure Healthcare, founded in 2018, is on a mission to transform the healthcare industry by making infusion therapy more affordable and accessible—while delivering a personalized, patient-centered experience. Pure specializes in treating chronic and autoimmune conditions such as Alzheimer's disease, multiple sclerosis, and rheumatoid arthritis, offering innovative, high-quality care tailored to individual needs. Its flagship offering, Pure Infusion Suites, has expanded to 43 locations across 14 states. These state-of-the-art suites prioritize patient comfort with private rooms, snacks, and entertainment, all while significantly lowering the cost of infusion services. Pure Healthcare also alleviates the administrative burden for referring providers by supporting patient authorizations and fostering strong partnerships with insurers, ensuring a seamless and efficient care journey from referral to treatment. The transaction is expected to close in the fourth quarter of 2025, and remains subject to customary closing conditions, including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Holland & Knight is serving as legal counsel for AleraCare. Kunzler Bean & Adamson is serving as legal counsel and Cantor Fitzgerald is acting as financial advisor for PURE Healthcare. About AleraCare AleraCare is a leading provider of infusion treatments and pharmacy services for high-need and medically complex populations. The company's core lines of business include ambulatory infusion centers, home infusion therapy and specialty pharmacy. AleraCare provides care to patients in over 30 locations across six states throughout the U.S., including Arizona, California, Colorado, Idaho, New Mexico and Utah. For more information, please visit About PURE Healthcare Pure Healthcare, founded by BUILD Capital Partners in 2018, is a national medical group dedicated to reducing healthcare costs and improving outcomes for patients with complex chronic and autoimmune conditions like rheumatoid arthritis, Crohn's disease, multiple sclerosis, and Alzheimer's. As a market leader in infusion therapy, Pure Healthcare operates Pure Infusion Suites alongside specialty clinics in rheumatology and neurology, including Memory Treatment Centers and Montana Arthritis Centers. Through strategic payer partnerships, streamlined patient authorizations, and a commitment to personalized, high-quality care, Pure Healthcare delivers scalable value to patients, providers, and payers nationwide. Learn more at View source version on Contacts Media Contacts:AleraCare Mike GellerProfile Advisorsmgeller@ Pure Healthcare Andy Sortormarketing@
Yahoo
an hour ago
- Yahoo
Staying up late on the weekends could make this common sleep disorder worse
Staying up late over the weekend could make a common sleep disorder worse, a new study has found. An estimated 936 million adults worldwide suffer from obstructive sleep apnoea (OSA), which is when the airways repeatedly collapse during sleep, causing pauses in breathing, frequent sleep disruptions, loud snoring, and daytime fatigue. The latest study suggests the sleep disorder's actual toll may be even greater, after researchers identified a spike in severity over the weekends driven by lifestyle choices and irregular sleep. 'Sleep is already a major public health issue, but our findings suggest its true impact may be underestimated,' Lucia Pinilla, one of the study's authors and a sleep researcher at Flinders University in Australia, said in a statement. 'Most clinical diagnostic testing is done on a single night, typically a weeknight, missing the weekend effect we're now calling 'social apnoea,'' she added. Related Blowing a conch shell: Could this ancient practice improve your sleep? Pinilla's team analysed data for about 70,000 people worldwide whose sleep quality was tracked using a monitor placed under their mattresses. Sleep disruptions were much more common over the weekends, the study found. People were 18 per cent more likely to have moderate or severe OSA on Saturdays compared to Wednesdays. Changes to sleep schedules – either staying up late or sleeping in – worsened sleep apnoea. For example, sleeping an extra 45 minutes on weekends raised the risk of severe sleep disruptions by 47 per cent. Lifestyle and age-related factors also appear to play a role. Adults ages 60 or older had a 7 per cent higher risk on weekends, compared with 24 per cent of those under 60. Related How much sleep do we really need? Here's what the experts say The findings were published in the American Journal of Respiratory and Critical Care Medicine. How sleep apnoea affects health Sleep apnoea can have more serious consequences than a poor night's rest. If left untreated, the condition may raise the risk of heart disease, diabetes, stroke, depression, and dementia. Pinilla warned that the weekend spike could raise the risk of these health issues even more. Many people with OSA use a continuous positive airway pressure (CPAP) machine when they sleep to ensure regular airflow and prevent breathing interruptions and snoring overnight. Danny Eckert, one of the study's authors, said people with OSA should also try to maintain a regular sleep routine and get seven to nine hours of sleep per night, even on the weekends. 'Keeping a fixed wake-up time and using your prescribed OSA therapy, even on weekends, and going to bed when you feel sleepy will help ensure you frequently get enough restorative sleep which can help combat the weekend spike in OSA,' Eckert said.
Yahoo
an hour ago
- Yahoo
Saudi Arabia Osteoporosis Drugs Market Analysis Report 2025-2033 Featuring Amgen, Eli Lilly and Co, F. Hoffmann La Roche, GlaxoSmithKline, Merck, Novartis, Pfizer, Teva Pharmaceutical, UCB
The Saudi Arabia Osteoporosis Drugs Market is projected to grow from US$ 210.89 million in 2024 to US$ 308.84 million by 2033, with a CAGR of 4.33% from 2025. Major growth drivers include an aging population, increasing osteoporosis rates, and favorable healthcare regulations. While bisphosphonates remain popular for their cost-effectiveness, biologics are expected to see the fastest growth. Government initiatives under Vision 2030 support local drug production and healthcare infrastructure, enhancing drug accessibility. However, challenges such as low adherence and rural access remain. Key market players include Amgen, Eli Lilly, and Pfizer. Saudi Arabian Osteoporosis Drugs Market Dublin, Aug. 13, 2025 (GLOBE NEWSWIRE) -- The "Saudi Arabia Osteoporosis Drugs Market to Reach US$ 308.84 Million by 2033 - 4.33% CAGR Driven by Biologics and Aging Population" report has been added to Saudi Arabia Osteoporosis Drugs Market is expected to reach US$ 308.84 million by 2033 from US$ 210.89 million in 2024, with a CAGR of 4.33% from 2025 to 2033 Due to improved healthcare infrastructure, the Saudi Arabian market for osteoporosis medications is concentrated in urban areas like Riyadh, Jeddah, and Dammam, whereas rural areas have less access to experts, diagnostics, and treatment alternatives. Growing rates of osteoporosis, the quick uptake of biologics, and advantageous healthcare laws in a number of Saudi Arabian nations are the main causes of this expansion. While bisphosphonates continue to dominate in volume due to their cost effectiveness, the biologics segment is anticipated to grow at the quickest rate. Government programs under Vision 2030, which prioritize regional medication production and improved healthcare infrastructure, promote the pharmaceutical industry. Osteoporosis treatments are becoming more accessible and reasonably priced as a result of these initiatives, and both name brand and generic medications are essential in satisfying the rising calcitonin, parathyroid hormone analogs, selective estrogen receptor modulators (SERMs), and monoclonal antibodies are among the available treatments. Newer biologic medicines are steadily gaining traction because of their increased efficacy and better patient outcomes, even if bisphosphonates are still frequently administered. Despite progress, issues like poor drug adherence, low awareness in rural regions, and underdiagnosis still exist. Additionally, comprehensive nationwide screening programs and coordinated post fracture care are lacking. Reducing the long term economic cost of osteoporosis in the nation and improving treatment outcomes could be achieved by addressing these challenges through integrated care models, digital health technologies, and Factors Driving the Saudi Arabia Osteoporosis Drugs Market Growth Saudi Arabia's Aging Population Is GrowingBecause osteoporosis and aging are closely related, Saudi Arabia's aging population is a major factor driving up demand for osteoporosis medications. People are more susceptible to fractures, loss of bone density, and associated problems as they get older, especially those over?60. The need for long term therapeutic treatments as well as preventive measures is growing as a result of this demographic shift. More people are reaching the age range where osteoporosis becomes a major concern due to better healthcare and longer life expectancies. As a result, the incidence of osteoporosis is rising in areas with greater populations of elderly persons. In order to assist the aging population and lessen the health burden associated with fractures, this development emphasizes the urgent need for efficient drugs and healthcare Rates of Screening and DiagnosisEarly osteoporosis identification has increased throughout Saudi Arabia thanks to the availability of sophisticated diagnostic technologies including dual energy X ray absorptiometry (DEXA) and bone mineral density (BMD) scanning. These technologies are now widely used in hospitals and clinics, increasing screening accessibility for high risk populations, especially postmenopausal women. In order to encourage early testing and diagnosis, health authorities are aggressively promoting awareness and screening initiatives. Because of this, more people are being diagnosed with bone loss early on, when treatment can be most successful. The number of patients eligible for osteoporosis treatments has increased dramatically due to the increase in early detection, which has increased demand for pharmacological interventions and made it possible to control the condition more effectively over the long Initiated Medical ProgramsAs a national health issue, osteoporosis is being actively addressed by the Saudi Arabian government. It seeks to lower the frequency of fractures and enhance bone health outcomes through education programs, public health campaigns, and preventative measures. Osteoporosis screening and bone density monitoring are becoming more commonplace in national health programs, and access to therapies is being facilitated by drug reimbursement policies and subsidized treatment options. These programs are promoting earlier medical intervention and increasing treatment adherence. Additionally, by making strategic investments in public health, the government's Vision 2030 push for local pharmaceutical development and a larger healthcare infrastructure is bolstering the availability of osteoporosis medications and promoting long term market in the Saudi Arabia Osteoporosis Drugs Market Low Persistence and Adherence to TreatmentLow patient adherence and persistence with prescribed medication regimens is one of the main issues facing Saudi Arabia's osteoporosis management. A lack of immediate, apparent benefits, worries about long term health repercussions, or worries about adverse effects cause many patients to stop treatment too soon. Non-adherence is also influenced by cultural norms and a lack of knowledge about how osteoporosis progresses. Treatment results are harmed as a result, raising the risk of fractures and associated problems. Long term patient involvement is challenging for healthcare practitioners, particularly when patients need daily or weekly oral medication. Enhancing patient education, providing alternate dosage regimens, and incorporating follow up assistance may all contribute to increased adherence and improved population wide therapeutic Treatment Persistence and AdherencePoor patient perseverance and adherence to prescribed treatment regimens is one of the main issues facing osteoporosis care in Saudi Arabia. Due to worries about side effects, worries about long term health repercussions, or a lack of obvious, immediate advantages, many patients stop treatment too soon. Non-adherence is further exacerbated by cultural attitudes and a lack of knowledge regarding the progressive nature of osteoporosis. Treatment results suffer as a result, and the risk of fractures and associated complications rises. It can be challenging for healthcare professionals to stay in touch with patients over the long term, particularly when they need daily or weekly oral medication. Enhancing follow up assistance, providing alternate dose schedules, and improving patient education may all contribute to increased adherence and improved therapeutic efficacy for the general public. Company Analysis: Overview, Key Persons, Recent Developments, SWOT Analysis, Revenue Analysis Amgen Inc. Eli Lilly and Company F. Hoffmann La Roche AG GlaxoSmithKline Plc Merck & Co. Inc. Novartis AG Pfizer Inc. Teva Pharmaceutical Industries Ltd. UCB S.A. Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $210.89 Million Forecasted Market Value (USD) by 2033 $308.84 Million Compound Annual Growth Rate 4.3% Regions Covered Saudi Arabia Key Topics Covered: 1. Introduction2. Research & Methodology2.1 Data Source2.1.1 Primary Sources2.1.2 Secondary Sources2.2 Research Approach2.2.1 Top-Down Approach2.2.2 Bottom-Up Approach2.3 Forecast Projection Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. Saudi Arabia Osteoporosis Drugs Market5.1 Historical Market Trends5.2 Market Forecast6. Market Share Analysis6.1 By Product Type6.2 By Route of Administration6.3 By States7. Product Type7.1 Bisphosphonates7.2 Calcitonin7.3 Rank Ligand Inhibitor7.4 Parathyroid Hormone Therapy (PTH)7.5 Selective Estrogen Receptor Modulators (SERMs)7.6 Sclerostin Inhibitor7.7 Others8. Route of Administration8.1 Oral8.2 Injectable8.3 Others9. Top States9.1 Dhahran9.2 Riyadh9.3 Khobar9.4 Jeddah9.5 Dammam9.6 Others10. Value Chain Analysis11. Porter's Five Forces Analysis11.1 Bargaining Power of Buyers11.2 Bargaining Power of Suppliers11.3 Degree of Competition11.4 Threat of New Entrants11.5 Threat of Substitutes12. SWOT Analysis12.1 Strength12.2 Weakness12.3 Opportunity12.4 Threats13. Pricing Benchmark Analysis13.1 Amgen Inc.13.2 Eli Lilly and Company13.3 F. Hoffmann-La Roche AG13.4 GlaxoSmithKline Plc13.5 Merck & Co. Inc.13.6 Novartis AG13.7 Pfizer Inc.13.8 Teva Pharmaceutical Industries Ltd.13.9 UCB S.A.14. Key Players Analysis For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Saudi Arabian Osteoporosis Drugs Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900